Back to News
Market Impact: 0.3
Equillium Gains Australian Nod For Phase 1 Study Of EQ504; Dosing In Nov'26
Source: Nasdaq
Healthcare & Biotech
Equillium received clearance from Australia's Human Research Ethics Committee and Therapeutic Goods Administration to proceed with a Phase 1 trial evaluating EQ504 for ulcerative disease. The article provides no additional trial details or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EQ0.55
More News
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Halozyme stock rises after winning injunction against Merck
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- BTIG cuts ArriVent BioPharma stock price target on trial results
- MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline
- Healthcare Services Group acquires NEXDINE Hospitality for $93.5M